[ Gilead – COVID-19 RFP Program COMMIT | Research Funding ]
Event details
| Date | 03.08.2020 |
| Category | Call for proposal |
Aim: In an effort to further address the unmet medical need in COVID-19, Gilead Medical Affairs is launching the COMMIT program. Successful projects should demonstrate clear objectives, defined timelines, a comprehensive operational plan, and propose data that has relevance to the medical community. Note: these projects will not have objectives/endpoints that overlap with studies that are known to be currently underway as of the day of the approval of the proposal, including those studies that are sponsored by either Gilead and/or third parties.
Gilead will consider support for research proposals that meet one of the following criteria:
Funding: max. $250,000
Duration: 6-9 months
Eligibility: Funding request for sole purpose of screening costs is not acceptable for COMMIT. Funding for or contribution of study drug is not acceptable for COMMIT. Gilead will not consider proposals that requests remdesivir or other study drug.
How to Apply: The first application stage includes submitting a Letter of Intent. The LOI should include a budget (<250K USD) inclusive of overhead costs and applicable taxes. Contact the Research Office if you have questions on these figures. The research plan submitted with the LOI should not exceed 1,000 words. The top applicants from the LOI stage will be asked to submit a full application.
Deadline: 03 August 2020 (4:30 PM PST)
Further information
Gilead will consider support for research proposals that meet one of the following criteria:
- Expand data on clinical course and outcome in vulnerable populations
- Long-term sequelae (i.e., pulmonary fibrosis, neurologic, cardiac, quality of life)
- Real world safety and effectiveness of remdesivir used alone or with other agents (JAK inhibitors, IL-6 inhibitors, convalescent plasma and ACE inhibitors and ARBs)
Funding: max. $250,000
Duration: 6-9 months
Eligibility: Funding request for sole purpose of screening costs is not acceptable for COMMIT. Funding for or contribution of study drug is not acceptable for COMMIT. Gilead will not consider proposals that requests remdesivir or other study drug.
How to Apply: The first application stage includes submitting a Letter of Intent. The LOI should include a budget (<250K USD) inclusive of overhead costs and applicable taxes. Contact the Research Office if you have questions on these figures. The research plan submitted with the LOI should not exceed 1,000 words. The top applicants from the LOI stage will be asked to submit a full application.
Deadline: 03 August 2020 (4:30 PM PST)
Further information
- More information about the program is available here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free